DELPHARM BLADEL’s Post

Since 2003, the Identification of Medical Products (IDMP) has played a crucial role in globally synchronizing data throughout the drug development lifecycle. At its essence, IDMP provides distinctive identification for pharmaceutical products and standardizes product information by employing five international ISO standards, ensuring adherence to global compliance standards. Strategic pharmaceutical companies can extend the utility of IDMP beyond its foundational purpose, utilizing it as a versatile information and data tool to generate added value. Learn how: #dassaultsystèmes #digitaltransformation #biopharma #idmp http://go.3ds.com/TRr

Malaysia NPRA implement Guideline on Facilitated Registration Pathway: Abbreviated and Verification Review with the aim of increasing the efficiency of the NPRA in pharmaceutical product registration The updates include an expansion of the scope of products, the addition of more reference agencies/procedures, and a revision of timelines More details can be found in the link in the first comment #regulatoryaffairs #pharmaceuticalindustry

The Jordan FDA has announced an extension for the implementation of DataMatrix and serialization on secondary packaging for regulated pharmaceutical products. The new deadline is now set for 𝗗𝗲𝗰𝗲𝗺𝗯𝗲𝗿 𝟯𝟭, 𝟮𝟬𝟮𝟰. This extension provides pharmaceutical companies with additional time to comply with these regulations, which are designed to enhance traceability and combat counterfeit drugs. If you want to learn more about the serialization requirements in Jordan, read our article 👉 https://lnkd.in/e3EEjzpC #JordanFDA #PharmaSerialization #tracekey

We appreciate everyone who joined our session on "Key Regulatory Changes in the Pharmaceutical Sector: UCPMP, Schedule M & Beyond." Sonal Sharma, Head of legal at MENARINI Group, shared her expert perspectives on the latest developments in Schedule M, Good Manufacturing Practices (GMP) and UCPMP and their implications for the pharmaceutical industry.   Hear her thoughts in what kind of impact and changes, the Pharmaceutical companies have to undertake by the virtue of the new UCPMP 2024 regulation.   If you have missed the webinar catch the recording here: https://lnkd.in/gJHexJ-i   #PharmaceuticalRegulations #UCPMP2024 #Compliance #PharmaWebinar #IndustryUpdates

West experts Bettine Boltres, PhD and Ana Kuschel, PhD will both be presenting at the PDA Manufacturing Meets Legislation Workshop today! This interactive workshop brings experts from the pharmaceutical industry and the legislative sector together to discuss current challenges and best practices in drug manufacturing following the latest legal regulations, and we are proud to have such great leadership representing us in this space. #womeninstem

NATCO Pharma announced that its partner, Mylan Pharmaceuticals Inc., has reached a settlement with Novo Nordisk in a patent litigation case involving the blockbuster drug Ozempic. This settlement marks a significant development for both companies, as Ozempic has gained immense popularity in recent years for its effectiveness in managing blood sugar and promoting weight loss. NATCO and Mylan have been collaborating on the development of generic Ozempic (Semaglutide) products. The settlement of the patent dispute paves the way for the potential launch of generic versions of Ozempic in the United States. While the specific terms of the settlement remain confidential, this resolution is expected to have a positive impact on both companies' businesses. Ozempic is a prescription medication patented by Novo Nordisk. Its growing popularity has led to increased demand, and the availability of generic alternatives could offer patients more affordable options. This settlement is a testament to the ongoing competition within the pharmaceutical industry and the importance of resolving patent disputes to ensure access to essential medications. #NATCOPharma #Mylan #NovoNordisk #Ozempic #genericdrugs #pharmaceuticals #healthcare 

The United States Pharmacopeia (USP) chapter 665 marks a significant shift in how single-use systems (SUSs) are regulated in the pharmaceutical manufacturing sector. The final version was published in 2022 and will become mandatory by 2026, giving manufacturers a crucial window to prepare and adapt. Many challenges lie ahead for adopting the new USP 665 guidelines. How is your organization preparing for these changes? https://hubs.li/Q02NFB610 #biopharma

🎓Thrilled to announce my participation in the Generic Drugs Forum (GDF) 2024! 📈 Delving into Regulatory Considerations to Enhance Generic Drug Access, this virtual event on April 10-11 provided invaluable insights into the pharmaceutical landscape. 🔍Grateful for the opportunity to broaden my expertise in this vital field! 🚀 #ContinuousLearning #RegulatoryInsights #GenericDrugs

Since 2003, the Identification of Medical Products (IDMP) has played a crucial role in globally synchronizing data throughout the drug development lifecycle. At its essence, IDMP provides distinctive identification for pharmaceutical products and standardizes product information by employing five international ISO standards, ensuring adherence to global compliance standards. Strategic pharmaceutical companies can extend the utility of IDMP beyond its foundational purpose, utilizing it as a versatile information and data tool to generate added value. Learn how: #dassaultsystèmes #digitaltransformation #biopharma #idmp http://go.3ds.com/bgk

DID YOU KNOW? The first pharmaceutical company, Merck & Co., was founded in Germany in 1668. It was originally a small apothecary shop and has since grown into a global leader in the pharmaceutical industry. #admissionopen2024_2025 #FacultyDevelopmentProgramme #BPharm #education #dpharmacy #bestcollege #TopCollege #FDP #mpharm #highereducation #HIMT #Pharmacy #PharmacyEducation